Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing goodness-of-fit for evaluation of dose-proportionality.
Wolfsegger MJ, Bauer A, Labes D, Schütz H, Vonk R, Lang B, Lehr S, Jaki TF, Engl W, Hale MD. Wolfsegger MJ, et al. Among authors: engl w. Pharm Stat. 2021 Mar;20(2):272-281. doi: 10.1002/pst.2074. Epub 2020 Oct 15. Pharm Stat. 2021. PMID: 33063443
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Among authors: engl w. Int J Hematol. 2017 Nov;106(5):704-710. doi: 10.1007/s12185-017-2265-6. Epub 2017 May 26. Int J Hematol. 2017. PMID: 28550352 Clinical Trial.
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Among authors: engl w. Int J Hematol. 2018 Jan;107(1):123-124. doi: 10.1007/s12185-017-2369-z. Int J Hematol. 2018. PMID: 29149425
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P, Mullins ES, Konkle BA, McGuinn C, Park YS, Stasyshyn O, Zulfikar B, Engl W, Tangada S. Chowdary P, et al. Among authors: engl w. Haemophilia. 2020 Jul;26(4):e168-e178. doi: 10.1111/hae.14052. Epub 2020 Jun 28. Haemophilia. 2020. PMID: 32597029 Clinical Trial.
62 results